Exome Asset Management LLC
Reported holdings as of Q2 2026, from 11 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| GUARDANT HEALTH INC | GH | $10.1M | 67,500 | +2.29pp | 10q | -18.4%-$2.3M | |
| PRAXIS PRECISION MEDICINES I | PRAX | $9.1M | 27,205 | -1.96pp | 5q | -40.2%-$6.1M | |
| TG THERAPEUTICS INC | TGTX | $9.1M | 164,915 | - | new | NEW | |
| COGENT BIOSCIENCES INC | COGT | $8.1M | 210,523 | -0.52pp | 6q | -24.4%-$2.6M | |
| IONIS PHARMACEUTICALS INC | IONS | $7.0M | 88,177 | +0.04pp | 7q | -19.9%-$1.7M | |
| ELI LILLY & CO | LLY | $6.6M | 5,492 | +0.73pp | 11q | -21.7%-$1.8M | |
| ABIVAX SA | ABVX | $6.2M | 46,878 | - | new | NEW | |
| ALUMIS INC | ALMS | $5.8M | 204,418 | +0.37pp | 4q | -26.8%-$2.1M | |
| CYTOKINETICS INC | CYTK | $5.1M | 60,056 | -0.38pp | 8q | -42.1%-$3.7M | |
| ENLIVEN THERAPEUTICS INC | ELVN | $5.1M | 100,203 | -1.33pp | 3q | -54.5%-$6.1M | |
| VERA THERAPEUTICS INC | VERA | $4.2M | 97,276 | +0.18pp | 5q | -15.4%-$760.2K | |
| UNITEDHEALTH GROUP INC | UNH | $4.0M | 9,612 | +0.66pp | 3q | -25.3%-$1.4M | |
| 10X GENOMICS INC | TXG | $3.9M | 102,629 | +0.73pp | 5q | -33.4%-$2.0M | |
| NATERA INC | NTRA | $3.7M | 13,800 | +0.38pp | 11q | -26.0%-$1.3M | |
| UNIQURE NV | QURE | $3.7M | 81,056 | - | new | NEW | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $3.6M | 32,209 | +0.38pp | 2q | -20.6%-$929.5K | |
| MAZE THERAPEUTICS INC | MAZE | $3.4M | 114,692 | +0.74pp | 2q | +29.6%+$781.3K | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $3.3M | 137,115 | +0.52pp | 2q | -23.6%-$1.0M | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $3.2M | 166,493 | -0.08pp | 2q | -22.7%-$951.8K | |
| ALKERMES PLC | ALKS | $3.2M | 61,336 | +0.44pp | 2q | -27.1%-$1.2M | |
| LIQUIDIA CORPORATION | LQDA | $3.1M | 39,224 | +1.04pp | 5q | -14.4%-$524.0K | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $2.9M | 5,410 | -0.35pp | 4q | -23.3%-$890.2K | |
| GLAUKOS CORP | GKOS | $2.8M | 19,862 | +0.55pp | 4q | -4.8%-$141.4K | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $2.6M | 32,214 | +0.14pp | 4q | -29.5%-$1.1M | |
| AGIOS PHARMACEUTICALS INC | AGIO | $2.6M | 70,500 | -0.57pp | 3q | -43.6%-$2.0M | |
| CRESCENT BIOPHARMA INC. | CBIO | $2.3M | 127,769 | -0.04pp | 2q | -16.6%-$457.6K | |
| ASTRAZENECA PLC | AZN | $2.3M | 12,045 | - | new | NEW | |
| BOSTON SCIENTIFIC CORP | BSX | $2.1M | 48,347 | -0.30pp | 2q | HELD | |
| ADAGENE INC | ADAG | $2.1M | 488,293 | -0.23pp | 3q | -33.7%-$1.0M | |
| PENUMBRA INC | PEN | $2.0M | 6,300 | +0.16pp | 7q | HELD | |
| INTUITIVE SURGICAL INC | ISRG | $2.0M | 4,908 | -0.31pp | 11q | -22.8%-$576.6K | |
| VIKING THERAPEUTICS INC | VKTX | $1.9M | 47,861 | - | new | NEW | |
| OCULAR THERAPEUTIX INC | OCUL | $1.8M | 181,588 | - | new | NEW | |
| EQUILLIUM INC | EQ | $1.8M | 552,956 | - | new | NEW | |
| ASCENDIS PHARMA A/S | ASND | $1.8M | 6,573 | - | new | NEW | |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | $1.7M | 184,914 | -0.07pp | 6q | -21.0%-$461.7K | |
| CYTOMX THERAPEUTICS INC | CTMX | $1.7M | 460,067 | -0.20pp | 4q | -11.8%-$230.3K | |
| VERASTEM INC | VSTM | $1.6M | 429,041 | -0.73pp | 3q | -32.6%-$793.3K | |
| NEKTAR THERAPEUTICS | NKTR | $1.6M | 22,417 | - | new | NEW | |
| CLEARPOINT NEURO INC | CLPT | $1.5M | 83,636 | - | new | NEW | |
| INSMED INC | INSM | $1.5M | 13,873 | -1.34pp | 2q | -47.9%-$1.4M | |
| CARIS LIFE SCIENCES INC | CAI | $1.4M | 78,180 | - | new | NEW | |
| BRIDGEBIO PHARMA INC | BBIO | $1.4M | 18,359 | -1.75pp | 11q | -72.8%-$3.7M | |
| ZENAS BIOPHARMA INC | ZBIO | $1.3M | 52,443 | flat | 2q | -35.0%-$717.9K | |
| NOVABRIDGE BIOSCIENCES | NBP | $1.1M | 576,960 | -0.04pp | 4q | HELD | |
| ESTABLISHMENT LABS HLDGS INC | ESTA | $1.1M | 13,100 | +0.31pp | 9q | HELD | |
| RELAY THERAPEUTICS INC | RLAY | $889.3K | 47,531 | -0.88pp | 2q | -82.9%-$4.3M | |
| GERON CORP | GERN | $798.8K | 624,046 | - | new | NEW | |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | $709.7K | 10,110 | - | new | NEW | |
| COMPASS THERAPEUTICS INC | CMPX | $604.8K | 276,165 | - | new | NEW | |
| REPLIMUNE GROUP INC | REPL | $446.8K | 40,361 | - | new | NEW | |
| ARBUTUS BIOPHARMA CORP | ABUS | $240.8K | 50,166 | -0.03pp | 5q | -33.5%-$121.5K |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $131.4M | 81.1% |
| Healthcare Services | $15.3M | 9.4% |
| Medical Devices | $11.4M | 7.0% |
| Insurance | $4.0M | 2.5% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $162.1M | 52 | 15 | 1 | 32 | 18 | 44.6% | 45 |
| Q1 2026 | $193.3M | 55 | 22 | 4 | 23 | 27 | 42.4% | 45 |
| Q4 2025 | $209.1M | 60 | 26 | 5 | 15 | 34 | 42.7% | 44 |
| Q3 2025 | $165.1M | 68 | 30 | 10 | 13 | 25 | 37.2% | 45 |
| Q2 2025 | $134.5M | 63 | 26 | 8 | 18 | 22 | 36.3% | 46 |
| Q1 2025 | $112.5M | 59 | 25 | 14 | 14 | 25 | 39.2% | 46 |
| Q4 2024 | $133.1M | 59 | 24 | 4 | 30 | 24 | 37.0% | 45 |
| Q3 2024 | $293.6M | 59 | 30 | 24 | 3 | 23 | 35.9% | 45 |
| Q2 2024 | $112.3M | 52 | 28 | 6 | 10 | 29 | 40.3% | 95 |
| Q1 2024 | $116.8M | 53 | 28 | 7 | 10 | 27 | 40.0% | 45 |
| Q4 2023 | $101.1M | 52 | 0 | 0 | 0 | 0 | 42.2% | 46 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.